Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease
- 19 August 2008
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 9 (13), 2305-2316
- https://doi.org/10.1517/14656566.9.13.2305
Abstract
Background: Allogeneic hematopoietic stem cell transplantation offers great promise for the treatment of a variety of diseases including malignancies and other diseases of hematopoietic origin. However, morbidity and mortality due to graft-versus-host disease (GVHD) remain a major barrier to its application. Objective: This review will provide an overview of the pathophysiology of GVHD and discuss the recent advances in GVHD management in both preclinical and clinical studies. Methods: An extensive literature search on PubMed from 1995 to 2008 was performed. Results/conclusion: There has been much progress in our understanding of GVHD and finding new means to control acute GVHD. While these approaches hold promise, as yet none has been able to replace the standard methods we may use routinely to decrease the incidence of the condition.Keywords
This publication has 118 references indexed in Scilit:
- Importance of Interleukin-7 in the Development of Experimental Graft-Versus-Host DiseaseTransplantation and Cellular Therapy, 2008
- The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantationBlood, 2008
- Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host diseaseBlood, 2007
- Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)Blood, 2007
- CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantationBlood, 2007
- Prevention of graft-versus-host disease by anti–IL-7Rα antibodyBlood, 2007
- Infliximab for GVHD therapy in childrenBone Marrow Transplantation, 2007
- The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease MortalityTransplantation and Cellular Therapy, 2007
- Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantationBlood, 2005
- A novel triterpenoid induces transforming growth factor β production by intraepithelial lymphocytes to prevent ileitisGastroenterology, 2004